Kodiak Sciences Inc.
2631 Hanover Street
23 articles with Kodiak Sciences Inc.
Kodiak Sciences Inc. announced that management will present at the Jefferies 2019 Healthcare Conference in New York, NY on Thursday, June 6 at 2:00 p.m. Eastern Time.
Kodiak Sciences Inc. reported business highlights and financial results for the first quarter ended March 31, 2019.
Kodiak Sciences Inc. announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Wednesday, May 15, at 5:00 p.m. Pacific Time.
Kodiak Sciences Inc. announced that presentations on its research will be made at the Association for Research in Vision and Ophthalmology 2019 Annual Meeting, being held from April 28 – May 2 in Vancouver, Canada.
Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018.
The San Francisco Business Times recently looked at top alumni from Bay Area incubators. Some of those companies are now brand-name companies like Uber and Reddit. Here’s a look at the biotech companies on their list.
Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting
Kodiak Sciences Inc. announced that a presentation on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on February 9, 2019 in Miami, FL.
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
Kodiak Sciences Inc. today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective as of the open of the U.S. markets on Monday, December 24, 2018.
Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate
Rapid high-magnitude and durable treatment responses were seen at all dose levels tested in a heavily pre-treated Phase 1 patient population.
Kodiak Sciences Inc.today reported business highlights and financial results for the third quarter ended September 30, 2018.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
10/31/2018October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Kodiak Sciences Inc. today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of $10.00 per share.
Kodiak Sciences Inc. today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $10.00 per share.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
Kodiak Sciences Inc. today announced that it has launched an initial public offering of 9,000,000 shares of its common stock at an anticipated initial offering price between $13.00 and $15.00 per share
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
Kodiak Sciences Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.
Kodiak Sciences Announces Completion of Enrollment in the Company's Phase 1 Safety and Tolerability Study in Patients with Retinal Disease
Kodiak Sciences Inc. today announced that enrollment of patients in the company's phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient in was dosed on August 13, 2018.